|
Originally published In Press as doi:10.1074/jbc.M104097200 on June 28, 2001
J. Biol. Chem., Vol. 276, Issue 35, 33220-33232, August 31, 2001
The Autocatalytic Release of a Putative RNA Virus Transcription
Factor from Its Polyprotein Precursor Involves Two Paralogous
Papain-like Proteases That Cleave the Same Peptide Bond*
John
Ziebuhr §,
Volker
Thiel , and
Alexander E.
Gorbalenya¶
From the Institute of Virology and Immunology,
University of Würzburg, Versbacher Straße 7, 97078 Würzburg, Germany and ¶ Advanced Biomedical
Computing Center, Science Application International
Corporation/NCI-Frederick Cancer Research and Development Center,
Frederick, Maryland 21702-1201
Received for publication, May 7, 2001, and in revised form, June 26, 2001
 |
ABSTRACT |
The largest replicative protein of
coronaviruses is known as p195 in the avian infectious bronchitis virus
(IBV) and p210 (p240) in the mouse hepatitis virus. It is
autocatalytically released from the precursors pp1a and pp1ab by
one zinc finger-containing papain-like protease (PLpro) in
IBV and by two paralogous PLpros, PL1pro and PL2pro, in
mouse hepatitis virus. The PLpro-containing proteins have been recently
implicated in the control of coronavirus subgenomic mRNA synthesis
(transcription). By using comparative sequence analysis, we now show
that the respective proteins of all sequenced coronaviruses
are flanked by two conserved PLpro cleavage sites and share a complex
(multi)domain organization with PL1pro being inactivated in IBV. Based
upon these predictions, the processing of the human coronavirus 229E
p195/p210 N terminus was studied in detail. First, an 87-kDa protein
(p87), which is derived from a pp1a/pp1ab region immediately upstream
of p195/p210, was identified in human coronavirus 229E-infected cells.
Second, in vitro synthesized proteins representing
different parts of pp1a were autocatalytically processed at the
predicted site. Surprisingly, both PL1pro and PL2pro cleaved between
p87 and p195/p210. The PL1pro-mediated cleavage was slow and
significantly suppressed by a non-proteolytic activity of PL2pro. In
contrast, PL2pro, whose proteolytic activity and specificity were
established in this study, cleaved the same site efficiently in the
presence of the upstream domains. Third, a correlation was observed
between the overlapping substrate specificities and the parallel
evolution of PL1pro and PL2pro. Collectively, our results imply that
the p195/p210 autoprocessing mechanisms may be conserved among
coronaviruses to an extent not appreciated previously, with PL2pro
playing a major role. A large subset of coronaviruses may employ two
proteases to cleave the same site(s) and thus regulate the expression
of the viral genome in a unique way.
 |
INTRODUCTION |
All positive-stranded RNA viruses infecting vertebrates, but also
many other RNA viruses, employ proteolytic processing as the major
regulation mechanism in virus genome expression. The virion RNA enters
ribosomes and directs the synthesis of one or two multidomain protein
precursors (polyproteins) that, in a controlled fashion, are
proteolytically processed by viral and, sometimes, cellular proteases
to produce intermediate and mature products. This processing proceeds
in cis and in trans at interdomain junctions that
contain the specific signals recognized by proteases (1-3).
We have been studying the protease-mediated regulation of viral gene
expression using human coronavirus strain 229E
(HCoV),1 which belongs to the
Coronaviridae family. Based on a similar polycistronic
genome organization, common transcriptional and (post)-translational
strategies, and a conserved array of nonstructural domains, the
Coronaviridae have been united with the
Arteriviridae in the order Nidovirales (Fig.
1A) (4, 5). With genome sizes of up to 32 kilobases, coronaviruses have the largest genomes among RNA
viruses, whereas the related arteriviruses are much smaller (13-16
kilobases). The positive-stranded genomic RNA of nidoviruses contains
5'- and 3'-nontranslated regions as well as 6-12 ORFs that, in some
cases, partially overlap each other. One of the most striking features
of the nidovirus life cycle is the specific mode of genome
transcription, which results in the synthesis of a 3'-coterminal,
nested set of 4-8 sg mRNAs. Except for the smallest transcript,
these sg mRNAs are structurally polycistronic (Fig. 1A),
but generally, only the most 5'-proximal ORF is translated (reviewed in
Ref. 6).

View larger version (52K):
[in this window]
[in a new window]
|
Fig. 1.
Outline of the HCoV life cycle and
proteolytic processing of the N-terminal regions of coronavirus
replicative polyproteins. A, ORFs in the polycistronic
genome are indicated as boxes. The replicase gene,
encompassing ORFs 1a and 1b, the gene for the surface glycoprotein
protein, S, the triple-spanning membrane protein,
M, and the nucleocapsid protein, N, are shown.
The filled rectangle at the 5' end of the genome represents
the common leader sequence that is also present at the 5' end of the
subgenomic mRNAs that are shown below the genome. The
conserved domains/functions encoded by the replicase gene are shown in
the boxes depicting the two replicative polyproteins (pp1a
and pp1ab). B, the N-terminal regions of the IBV, MHV, and
HCoV replicative polyproteins pp1a/pp1ab are shown with the previously
identified processing products and the corresponding cleavage sites (P1
and P1' residues indicated). The following abbreviations are used:
PL, papain-like protease; PL1, papain-like
protease 1; X, domain conserved in coronaviruses,
alphaviruses, rubiviruses, and hepatitis E virus (56); PL2,
papain-like protease 2; 3CL, 3C-like protease;
RdRp, RNA-dependent RNA polymerase;
Z, putative zinc finger; HEL, NTPase/RNA
helicase; C, conserved domain specific for nidoviruses
(4).
|
|
The two largest ORFs (ORF1a and ORF1b), which encompass the 5'-proximal
two-thirds of the genome, are believed to encode all the protein
functions required for nidovirus RNA synthesis (7, 8). The
ORF1b-encoded polyprotein, which includes the putative RdRp activity
and a recently established RNA helicase activity that is associated
with a unique zinc finger structure (9, 10), is only produced if a
ribosomal frameshift from ORF1a into ORF1b takes place during
translation (11). This translational strategy is expected to yield two
extremely large polyproteins, pp1a and pp1ab, of about 450 and 750 kDa,
respectively. To date, pp1a and pp1ab have not been detected in
vivo, most probably because they are cotranslationally and
autocatalytically processed into numerous processing intermediates and
mature nonstructural proteins. Both the number and the origin of most
of these proteins remain to be determined for coronaviruses (reviewed
in Ref. 12).
The coronavirus pp1ab can be divided into an N-terminal region that is
processed by one or two accessory papain-like proteases (Fig.
1B) and a C-terminal region that is processed by the main 3C-like cysteine protease (3CLpro) (12). The N-terminal region of
pp1a/pp1ab spans from the initiator Met to the N terminus of the 3CLpro
and consists of ~2800-3300 amino acids (Fig. 1B).
Although IBV contains only one papain-like protease (PLpro), which is
preceded by a conserved X domain, all other coronaviruses encode two
paralogous and sequentially positioned papain-like proteases (PL1pro
and PL2pro) that flank the X domain from both sides (13, 14). The IBV
PLpro is part of an ~1550-amino acid protein (p195) that is
autocatalytically released at flanking sites (15, 16). Cleavage at the
N terminus of p195 produces p87, which is the N-terminal processing
product of the IBV pp1a/pp1ab. In contrast, at least three proteins,
p28, p65, and p210 (also known as p240), are produced from this region
of pp1a/pp1ab in mouse hepatitis virus (MHV) (17-19). The MHV p210
protein, which is an ortholog of IBV p195, is autocatalytically
released through cleavages mediated by PL1pro at the N-terminal site
(20, 21) and PL2pro at the C-terminal site (22). PL1pro also cleaves
the p28 p65 junction (23, 24) which, except for IBV, is
conserved in all coronaviruses (25). Accordingly, a PL1pro-mediated
cleavage at this site, resulting in the production of a small
N-terminal protein (p9, p28 equivalent), was also detected in HCoV
(25). The IBV PLpro cleavage sites flanking p195, the MHV p28 p65,
and p65 p210 PL1pro cleavage sites and the HCoV PL1pro cleavage site
producing p9 were verified by site-directed mutagenesis and/or
N-terminal protein sequencing (15, 16, 21, 25-27). Irrespective of the
virus studied, the position in pp1a and the protease identity, all
established and predicted coronavirus PLpro/PL1pro cleavage sites,
contain a small amino acid (commonly Gly) at the P1 or P1' position, or at both positions.
Technically, coronavirus PLpros have only been characterized in
surrogate systems, since the extreme size of the coronavirus RNA genome
proved to be a serious obstacle to the development of straightforward
reverse genetic approaches (28-30). In most cases, the in
vitro results have been corroborated by the identification of
corresponding cleavage products in coronavirus-infected cells, and
thus, they are biologically relevant. Although the function of the
N-terminal region of pp1a/pp1ab is not known, both the transcription-negative phenotype of an alphavirus X domain mutant (31)
and the conservation of a transcription factor-like zinc finger in
coronavirus PLpros (32) indicated that p195/p210 might be involved in
coronavirus RNA synthesis. This hypothesis is strongly supported by a
recent report in which the equine arteritis virus nonstructural protein
1, which, most probably, is a distant homolog of the coronavirus
PLpros, is shown to be a transcriptional factor that is indispensable
for sg mRNA synthesis (33).
In this study, we analyzed the mechanism of the coronavirus p195/p210
processing. We updated our previous alignment for the poorly conserved
p195/p210 region (14) and found that p195/p210 (i) has a uniform domain
organization and (ii) is flanked by cleavage sites that are conserved
in all coronaviruses, including IBV. Contrary to the current
belief that IBV encodes only one PLpro, we show here that IBV, like
other coronaviruses, may in fact encode two PLpro domains as follows: a
proteolytically defective remnant of PL1pro and an active PL2pro,
currently known as PLpro. We then confirmed the identity of the
N-terminal site in HCoV and demonstrated this site to be cleaved by
either of the two PLpros, indicating that these proteases may be
(partly) redundant. The ability of PL1pro to cleave the cognate site
was found to be considerably down-regulated by flanking sequences that
included PL2pro. In contrast, PL2pro cleaved the same site more
efficiently in the presence of the upstream sequences. The combined
data suggest that the regulation of coronavirus genome expression may
include a unique autoproteolytic mechanism that recruits two paralogous proteases to cleave the same site.
 |
EXPERIMENTAL PROCEDURES |
Computer-aided Comparative Sequence Analyses--
Amino acid
sequences were derived from the Genpeptides data base. Sequence
alignments were produced using the ClustalX program (34), the Dialign2
program (35), and the Macaw workbench (36). Non-redundant sequence data
bases were searched with single sequences (37), and with Hidden Markov
models trained on multiple sequence alignments using the HMMER 2.0.1 package (38). Upon protein comparisons, the Blossum62 (39) was used as
the scoring inter-residues table. The obtained alignments were also
sent as inputs for the PhD program (40, 41) to predict secondary
structures and transmembrane helices. Cluster phylogenetic trees were
reconstructed using the neighbor-joining (NJ) algorithm of Saitou and
Nei (42) with the Kimura correction (43) and were evaluated with 1000 bootstrap trials, as implemented in the ClustalX program. Parsimonious
trees were generated through exhaustive search and evaluated with
bootstrap analysis using a UNIX version of the PAUP* 4.0.0d55 program
(44) that is included in the GCG-Wisconsin Package programs (Genetics Computer Group, Madison, WI). Trees were prepared and modified using
the TreeView program (45).
Virus and Cells--
The methods for HCoV propagation in MRC-5
cells (ECACC 84101801) and concentration of virus with polyethylene
glycol have been described previously (46).
Preparation of Antiserum -H2--
The HCoV ORF 1a nucleotide
sequence coding for the pp1a/pp1ab amino acids 112-322 was amplified
by PCR from pBS-J12E6 plasmid DNA (47) using primers 134 and 135. The
upstream primer contained a BamHI restriction site, and the
downstream primer contained a translation stop codon followed by a
PstI restriction site. The PCR product was digested with
BamHI and PstI and ligated with BamHI/PstI-digested pMal-c2 DNA (New England
Biolabs, Frankfurt, Germany). The resulting plasmid, pMal-H2, encoded
the specified ORF1a amino acids fused to the Escherichia
coli maltose-binding protein (MBP). The plasmid was used to
transform competent E. coli TB1 cells, and the bacterial
fusion protein was expressed and purified as described previously (46,
48). The HCoV-specific polypeptide, which contained 211 amino acids of
pp1a/pp1ab and is preceded by six N-terminal vector-derived amino
acids, was released from MBP by cleavage with endoprotease Xa (Amersham
Pharmacia Biotech) and used to immunize rabbits as described previously (46). The resulting antiserum was designated -H2.
Metabolic Labeling, Cell Lysis, and
Immunoprecipitation--
Infection or mock infection of MRC-5 cells
was done essentially as described previously (49). Briefly, 3 × 106 MRC-5 cells were mock-infected or infected with HCoV at
a multiplicity of 10 plaque-forming units per cell. Radioactive
labeling of newly synthesized proteins was done for 2.5 h, between
7 and 9.5 h postinfection, with 100 µCi of
L-[35S]methionine per ml. Before labeling,
the cells were washed twice with methionine-free minimal essential
medium supplemented with 2% dialyzed fetal bovine serum. The cells
were lysed in 1 ml of lysis buffer (46). One hundred microliters of
cell lysate was mixed with 400 µl of immunoprecipitation buffer (46)
and 5 µl of preimmune serum or 5 µl of -H2 serum. After 60 min
at 4 °C, 25 µl of protein A-Sepharose CL-4B (P9424; Sigma) was
added to isolate the immune complexes, which were washed and eluted as described previously (46). The immunoprecipitated proteins were analyzed by SDS-polyacrylamide gel electrophoresis in a 10-17% gradient gel and autoradiography.
Expression of pp1a/pp1ab Amino Acids by in Vitro
Translation--
Previously, the HCoV PL2pro coding sequence has been
found to be non-clonable in E. coli (47). We therefore used
PCR-based methods to express this region of the HCoV genome. If not
otherwise specified, we used a DNA template that had been isolated from a recombinant vaccinia virus, vHCoV-inf-1, carrying a complete cDNA
copy of the HCoV genome (30). The nucleotide sequences of all PCR
products used for in vitro RNA synthesis were determined to
exclude any PCR-derived nucleotide misincorporations. The amino acid
sequences of the proteins analyzed in this study are summarized in Fig.
2, and the primers used to generate
appropriate DNA templates for in vitro RNA synthesis are
given in Table I. To produce proteins pp717-1285, pp717-1436, pp717-1910, and pp759-1910, the coding sequences of the HCoV pp1a/pp1ab amino acids 717-1285, 717-1436, 717-1910, and 759-1910 were amplified by PCR using the primer pairs
111/103, 111/105, 111/107, and 110/107, respectively. The upstream
primers (110 and 111, respectively) contained a T7 RNA polymerase
promoter followed by an initiator Met codon and the downstream
primers (103, 105, and 107, respectively) contained a translation stop
codon. By using the purified PCR products as templates, capped RNAs
were synthesized in vitro by use of a Riboprobe T7 system
(P1440 and P1711; Promega, Mannheim, Germany) and subsequently translated in reticulocyte lysate (L4960, Promega) in the presence of
[35S]methionine as described previously (48). After 40 min, the translation reactions (15-µl mixtures) were stopped by the
addition of 1.7 µl of 10× translation stop mix (0.1 mg of RNase A
per ml, 10 mg of cycloheximide per ml, 5 mM
[32S]methionine), and the mixtures were divided into 2 aliquots. One of the aliquots was stored at 80 °C, and the other
one was further incubated at 30 °C for 120 min. Finally, 0.2 µl of
each reaction aliquot was analyzed by SDS-polyacrylamide gel
electrophoresis and autoradiography. To obtain quantitative data on the
extent of substrate conversion, the radioactivities incorporated into the full-length substrate and the C-terminal cleavage product were
determined using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA)
equipped with ImageQuant 1.1 software. The data obtained were adjusted
to the number of methionines present in the respective proteins, and
the calculations were done essentially as described by Teng et
al. (50).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 2.
Schematic representation of the N-terminal
HCoV pp1a/pp1ab region and the proteins tested for proteolytic
activity. The numbering of the amino acids is according to Ref.
47. The putative nucleophilic cysteine residues of PL1pro and PL2pro
are indicated. The positions of the PL1pro p9 p87 cleavage site (25)
and two additional PLpro cleavage sites (this study) are given. The
proteins tested for proteolytic activity are depicted on the
left, and the black lines designate these
proteins in relation to their positions in pp1a and pp1ab. See
"Experimental Procedures" for a description of the generation of
each expression construct.
|
|
Codon and Deletion Mutagenesis--
To generate
pp717-1285_C1054A, the coding sequence of pp1a/pp1ab amino acids
717-1285 was amplified by PCR using primers 111 and 103. The PCR
product was digested with NcoI and EcoRI and ligated into the NcoI-EcoRI site of plasmid pBST
(51). The resulting plasmid, pBST-111-103, was subjected to
site-directed mutagenesis by in vivo recombination PCR (48,
52) using primers 112 and 113. The resulting plasmid was designated
pBST-111-103_C1054A. Both pBST-111-103_C1054A DNA and the parental
pBST-111-103 DNA were linearized with EcoRI and used as
templates for RNA synthesis.
To generate pp717-1285_VM, an in vivo recombination PCR was
done using primers 188 and 189 and pBST-111-103 DNA as a template. The
resulting plasmid, pBST-111-103_VM, was linearized with
EcoRI and used as a template for RNA synthesis.
pp717-1285_VM contained the pp1a/pp1ab amino acids 717-1285 in which
each of the three valine residues, Val900,
Val906, and Val908, was replaced with
methionine (V900M, V906M, and V908M).
To generate pp717-1910_C1054A-VM, an in vivo recombination
PCR was done using primers 112 and 113 and pBST-111-103_VM plasmid DNA
as a template. The resulting plasmid, pBST-111-103_C1054A-VM, served
then as a template to amplify nucleotides 2441-3912 using primers 111 and 139. In a separate reaction, nucleotides 3881-6022 were amplified
from vHCoV-inf-1 genomic DNA by using primers 165 and 107. The two PCR
products were digested with BsaI, purified, and ligated
together by using T4 DNA ligase. The ligated product was then used as a
template for second round PCR amplification with outside primers 111 and 107. The resulting 3,614-base pair PCR product was used as a
template for RNA synthesis.
To generate pp717-1910_C1054A/W1702L, nucleotides 2441-3912 were
amplified from pBST-111-103_C1054A plasmid DNA by using primers 111 and 139, and nucleotides 3881-6022 were amplified from vaccinia virus
vF10 DNA2 by using primers
165 and 107. The recombinant vaccinia virus vF10 contained a cDNA
copy of the HCoV ORF1a in which codon 1702, TGG, has been changed to
TTG. The two PCR products were digested with BsaI and
ligated together with T4 DNA ligase. The ligated product was then used
as a template for second round PCR amplification with primers 111 and
107. The RNA derived from the purified PCR template encoded the
pp1a/pp1ab amino acids 717-1910 in which active-site residues of both
PL1pro and PL2pro have been replaced (C1054A and W1702L, respectively).
To generate pp717-1910_C1054A, nucleotides 2006-3451 and 3454-6022
were amplified by PCR from vHCoV-inf-1 genomic DNA in two separate
reactions by using the primer pairs 137/212 and 213/39, respectively. The two products were digested with BsaI and
ligated together with T4 DNA ligase. The ligated product was then used as a template for second round PCR amplification with primers 111 and
107. The RNA derived from the purified PCR template encoded the
pp1a/pp1ab amino acids 717-1910 in which the PL1pro catalytic Cys
residue has been replaced with Ala (C1054A).
To generate pp717-1910_ 1054-1061, nucleotides 2006-3451 and
3476-6022 were amplified by PCR from vHCoV-inf-1 genomic DNA in two
separate reactions by using the primer pairs 137/210 and 211/39,
respectively. The two products were digested with BsaI and
ligated together with T4 DNA ligase. The ligated product was then used
as a template for second round PCR amplification with primers 111 and
107. The RNA derived from the purified PCR template encoded the
pp1a/pp1ab amino acids 717-1053 and 1062-1910, i.e. residues 1054-1061 have been removed from PL1pro.
To generate pp717-1910_C1701A, nucleotides 2006-5392 and 5396-6022
were amplified by PCR from vHCoV-inf-1 genomic DNA in two separate
reactions by using the primer pairs 137/214 and 215/39, respectively.
The two products were digested with BsaI and ligated together with T4 DNA ligase. The ligated product was then used as a
template for second round PCR amplification with primers 111 and 107. The RNA derived from the purified PCR template encoded the pp1a/pp1ab
amino acids 717-1910 in which the PL2pro catalytic Cys residue has
been replaced with Ala (C1701A).
To generate pp717-1910_ 1701-1708, nucleotides 2006-5393 and
5426-6022 were amplified by PCR from vHCoV-inf-1 genomic DNA in two
separate reactions by using the primer pairs 137/167 and 168/39,
respectively. The two products were digested with BsaI and
ligated together with T4 DNA ligase. The ligated product was then used
as a template for second round PCR amplification with primers 111 and
107. The RNA derived from the purified PCR template encoded the
pp1a/pp1ab amino acids 717-1700 and 1709-1910, i.e. residues 1701-1708 have been removed from PL2pro.
N-terminal Protein Sequence Analysis--
The proteins
pp717-1285_VM and pp717-1910_C1054-VM were produced by in
vitro translation in the presence of [35S]methionine
as described above. After incubation of the translation reactions for
160 min, the products were separated by electrophoresis in
SDS-polyacrylamide gels and transferred electrophoretically to
polyvinylidene difluoride (PVDF) membranes (162-0180, Bio-Rad). The
areas of the membranes containing the C-terminal cleavage products were
identified by autoradiography and isolated. The bound proteins were
then subjected to 16 cycles of Edman degradation by use of a pulsed
liquid protein sequencer (ABI 467A, Applied Biosystems, Inc.,
Weiterstadt, Germany). The eluate from each cycle was mixed with
scintillation mixture, and the radioactivity was measured.
 |
RESULTS |
The Coronavirus p195/p210 Proteins Are Flanked by Conserved PLpro
Cleavage Sites and Share a Conserved Five-domain
Organization--
The N-terminal part of the replicative polyproteins
pp1a/pp1ab of coronaviruses is poorly conserved (14, 47). The
proteolytic domains responsible for the processing of this region are
part of the largest pp1a/pp1ab cleavage product, known as p195 in IBV and p210 in MHV. These proteins are autocatalytically processed by
non-identical mechanisms that, in the case of p195, involve a single
PLpro activity and, in the case of p210, both the PL1pro and PL2pro
activities (15, 16, 20, 22). Because of these differences, it remained
unknown whether the N and C termini of p195/p210 are conserved in
coronaviruses. Also, although we suspected that the IBV PLpro may be an
ortholog to PL2pro (13, 14), its relationship with the pair of PLpros
conserved in all other coronaviruses remained unresolved. By using
software for generating global alignments (ClustalX) and local
alignments (Dialign2 and Macaw), we have produced a coronavirus-wide
multiple sequence alignment which included p195/p210 together with
flanking sequences (Fig. 3). The
conserved features identified by this alignment include two cleavage
sites at the N and C termini and five domains in the order Ac, PL1pro,
X, PL2pro and Y, where Ac is the N-terminal domain and Y is the
C-terminal domain as defined in this study (see below).

View larger version (95K):
[in this window]
[in a new window]
|
Fig. 3.
Multiple sequence alignment of the p195/p210
regions of coronavirus replicase polyproteins. An initial draft of
this alignment was generated using the Dialign2 program (35) and
subsequently improved with the ClustalX program (34). The alignment was
further checked and corrected using results of a Macaw-mediated (36) analysis
that involved all coronaviruses except MHVJ, which was excluded due to
its closeness to MHVA. Five domains were recognized in the alignment,
and their positions were indicated with ><. The borders of the
domains are tentative. The alignments of the PL1pro and PL2pro regions
were based on results of our previous analysis (32). For two regions
that are located between domains X and PL2pro, and PL2pro and Y,
respectively, no consistent alignments have been produced. Therefore,
only the sizes of these regions are indicated. The pp1a position of the
rightmost residue in an alignment row is indicated at the right
side. The shading of individual residues in the
alignment was done according to a four-level conservation; black
background and white letters, gray background and
white letters, gray background and black letters,
respectively, indicate residues that are conserved in 100, 80, and 60%
of the sequences. Groups of conserved amino acids are as follows: IVLM;
FYW; KRH; DNQE; ST; AG. According to the Macaw, four blocks, which are
labeled with letters from A to D above
the alignment and are discussed in the main text are statistically
significant for the entire pp1a searching space: A,
p = 1.1e 002; B,
p = 2.1e 002; C,
p = 4.2e 006; and D,
p = 3.9e 015. Two hydrophobic regions
predicted to be trans-membrane domains (40) are marked with
dashed lines and denoted with TM1 and TM2, respectively.
Other highlights are as follows: +, catalytic Cys and His
residues of PLpros; #, postulated metal-chelating Cys and
His residues of the PLpro zinc fingers; @, conserved Cys
and His residues of domain Y; |, cleavage sites of PLpros. MHVA and
MHVJ, MHV strains A59 and JHM. The National Center for Biotechnology
Information sequence ID: IBV, 138147; HCoV, 464694; TGEV, 872319; MHVA,
453423 (nucleotide); MHVJ, 266958 (corrected according to Ref. 57); all
sequences are for proteins unless otherwise specified.
|
|
Block A is the only conserved sequence block that was identified
upstream of PL1pro. This block is part of a newly recognized domain
that varies in size among the different coronaviruses (~150-240 amino acids). Because this domain is highly enriched in acidic Asp and
Glu residues, it was named Ac (acidic domain). PL1pro was
previously identified in all coronaviruses except IBV. Our alignment
shows that IBV may in fact encode a deviant form of PL1pro, which, like
its counterparts in other coronaviruses, is located between the Ac and
X domains and contains a conserved sequence around the catalytic Cys
residue (block B). We consider this domain to be enzymatically
defective because, in contrast to other coronaviruses, the other
conserved sequences essential for proteolytic activity (e.g.
catalytic His residue and zinc finger) are missing in the IBV sequence.
The assignment of this domain as a PL1pro remnant is consistent with
the PL2pro-like features observed for the IBV PLpro. Thus, both the
coronavirus PL2pros and the IBV PLpro occupy similar positions in
pp1a/pp1ab; they are embedded between nonconserved regions of variable
sizes that, on the upstream side, separate the X domain from
PL2pro/PLpro and, more downstream, PL2pro/PLpro from the Y domain.
Furthermore, immediately upstream of the catalytic Cys residue, both
the PL2pros and PLpro (but not the PL1pros), share a moderately
conserved region of ~80 amino acids, which includes the particularly
conserved block C. These observations suggest that the p195/p210
proteins of all coronaviruses have a uniform domain organization and
include two PLpros. In IBV, one of these proteases (PL1pro) is
proteolytically defective and the other one (PL2pro) is proteolytically
active. (Henceforth, we use PL2pro rather than PLpro to refer to the
proteolytically active papain-like protease of IBV).
The largest conserved domain identified in this study encompasses a
region of ~450-490 amino acids at the C terminus of all coronavirus
p195/p210 proteins. It was named Y domain. This domain contains two
highly hydrophobic stretches and 11 conserved Cys/His residues (14),
all in the N-terminal ~180 amino acids. These structural features
lead us to predict that the Y domain may anchor p195/p210 into
membranes and bind Zn2+ or similar metal ions. Overall, the
multidomain organization of p195/p210 implies that the protein is multifunctional.
The conservation of the cleavage sites flanking p195/p210 was
recognized on the basis of the immediate proximity of these sites to
sequence blocks whose identification proved to be statistically rigorous. The cleavage sites previously identified at the p65 p210 junction in MHV (Ala Gly) and the p87 p195 junction in IBV
(Gly Gly) matched one another in a region upstream of the conserved
sequence block A (Fig. 3). In HCoV and porcine transmissible
gastroenteritis virus (TGEV), previously uncharacterized Gly-Gly
dipeptides with similar positions were identified as putative cleavage
sites. Likewise, all coronaviruses have putative cleavage sites of
similar composition (Gly Gly, Gly Ala, Ala Gly, or Ser Gly) in
the vicinity of the C terminus of block D. Strikingly, after this
analysis was performed, one of these predicted sites, Gly Gly, proved
to be cleaved by PL2pro at the p195 p41 junction in IBV (16).
Similarly, the preliminary mapping data obtained recently for the MHV
PL2pro p210 p44 cleavage site (22) are compatible with the location of the predicted Gly Ala scissile bond.
In this study, we were specifically interested in relating the
implications of the sequence analysis to the understanding of the
autocatalytic release mechanisms of p195/p210 in HCoV, which have not
been characterized to date. In particular, we were intrigued by the
observation that the cleavage at the N terminus of p195/p210 is
apparently mediated by different paralogous proteases in two
coronaviruses, namely by PL2pro in IBV and PL1pro in MHV (see above;
Fig. 1B). Furthermore, this site was not cleaved by the HCoV
PL1pro in different in vitro assays, although the enzyme was
shown to be active at the p9 87 junction in mono- and bimolecular assays (25, 32). In light of this striking variation, we reasoned that
the comprehensive characterization of this cleavage in HCoV should be
especially informative, and we did the following experiments.
Size and Origin of a 87-kDa Protein Identified in HCoV-infected
Cells Are Compatible with Cleavage at the Predicted N Terminus of
p195/p210--
The results of the comparative sequence analysis
described above led us to predict a second processing product in the
N-terminal proximal region of HCoV pp1a/pp1ab. We expected this protein
to be derived from a pp1a/pp1ab region immediately downstream to the
previously identified HCoV p9 polypeptide (25) and upstream of the
putative HCoV p195/p210. This protein is predicted to be released
through cleavages at Gly111 Asn112 and
Gly897 Gly898 and would have a calculated
molecular mass of 87,345. To test this prediction, we first generated a
polyclonal antiserum, -H2, specific for the N-terminal region of the
predicted protein (pp1a/pp1ab amino acids Asn112 to
Gln322). The antiserum was used to immunoprecipitate
ORF1a-encoded polypeptides from HCoV-infected MRC-5 cells. The results
of this experiment, shown in Fig. 4,
revealed two major proteins that had apparent molecular masses of 87 (p87) and 230 kDa (p230). The proteins were specifically precipitated
by immune serum from metabolically labeled lysates of HCoV-infected
cells (Fig. 4, lane 4). They did not react with preimmune
serum and were not present in mock-infected cells (Fig. 4, lanes
1-3). Taking into account the specificity of antiserum -H2 and
the size of the protein, the data are fully consistent with the initial
model that p87 represents a pp1a/pp1ab processing product that is
released from the polyprotein by cleavages at (or near) the predicted
sites, Gly111 Asn112 and
Gly897 Gly898.

View larger version (53K):
[in this window]
[in a new window]
|
Fig. 4.
Detection of an ORF1a-encoded 87-kDa cleavage
product in HCoV-infected cells. Metabolically labeled lysates from
3 × 105 mock-infected (M) (lanes
1 and 3) or HCoV-infected (I) (lanes
2 and 4) MRC-5 cells were analyzed by
SDS-polyacrylamide gel electrophoresis in a 10-17% acrylamide
gradient gel after immunoprecipitation with -H2 antiserum
(lanes 3 and 4) or the corresponding preimmune
serum (lanes 1 and 2). Antiserum -H2
recognizes the HCoV ORF1a-encoded amino acids 112-322. The cells were
labeled from 7 to 9.5-h postinfection with 100 µCi of
[35S]methionine per ml. Sizes of molecular mass markers
(CFA 626; Amersham Pharmacia Biotech) with masses in kilodaltons as
well as the 230- and 87-kDa processing products, p230 and p87,
respectively, are indicated.
|
|
Unlike p87, the origin of p230 remains uncertain from the obtained
data. To resolve whether p230 is a precursor protein of p87 or whether
it was coprecipitated by the -H2 antiserum due to specific
interactions with p87, more experiments involving antisera with new
specificities are to be performed.
Approach to Analyze the Processing at the Predicted p87 p195/p210
Junction in Vitro--
Next, we analyzed the processing at the
p87 p195/p210 junction in vitro. In the past, proteins
encompassing the entire p87 or a large portion of it at the N terminus
and PL1pro at the C terminus were not processed at the predicted
p87 p195/p210 cleavage site in HCoV in vitro (25, 32). The
observed stability of the precursors might be due to the inability of
PL1pro to process this site or an incorrect assignment of this HCoV
site by the computer-assisted analysis (Fig. 3). Alternatively, the
PL1pro-mediated cleavage at this site could be inhibited by p87, as was
previously observed for another coronavirus, MHV (20). (It should be
noted that these aspects have not been discussed in the original
studies (25, 32) as they are brought to light by the computer-based analysis described in Fig. 3).
To exclude the potential negative effect of p87 on the p87 p195/p210
processing in this study, we expressed proteins that contained only
small fragments of p87 (~140-180 amino acids) immediately adjacent
to the predicted C terminus of this protein. By PCR, we produced four
DNAs that contained a T7 RNA polymerase promoter, a Met initiator
codon, and different 3'-extensions encoding the pp1a/pp1ab amino acids
Val717 to Pro1910 or truncated versions of it
(Fig. 2). In total, four basic constructs and eight mutated variants
were designed. All constructs shared the predicted HCoV pp1a/pp1ab
Gly897 Gly898 cleavage site, preceded by a
small domain and followed by the Ac-PL1pro domains. In three of the
basic constructs, this minimal sequence was extended to include either
the X domain alone or both the X and PL2pro domains. Furthermore,
two basic constructs, pp717-1285 and pp717-1910, were subjected to
site-directed mutagenesis, for example, to inactivate the PL1pro and
PL2pro domains or to allow radiosequence analyses of
[35S]methionine-labeled cleavage products (for details on
the constructs, see "Experimental Procedures" and Fig. 2). By using
these PCR templates, capped RNAs were generated and translated in
reticulocyte lysates to characterize the cleavage at the predicted
junction by SDS-polyacrylamide gel electrophoresis and N-terminal
protein sequence analysis.
HCoV PL1pro Can Cleave the Conserved Site at the Predicted
p87 p195/p210 Junction--
First, the involvement of PL1pro in the
cleavage of the p87 p195/p210 junction was addressed. To this end,
the proteolytic processing of pp717-1285, a protein that contained
PL1pro but lacked the X and PL2pro domains, was characterized. We
analyzed the processing of the wild-type protein and a mutant,
pp717-1285_C1054A, in which the catalytic Cys-1054 of PL1pro was
replaced with Ala. Previously, this mutation was proved to block the
PL1pro-mediated cleavage of the p9 p87 junction (25). Upon in
vitro translation of RNAs encoding pp717-1285 and
pp717-1285_C1054A, respectively, numerous products were detected after
40 min. The most prominent protein had an apparent molecular mass of
~70 kDa, which corresponded well to the expected size of the primary
translation product (Fig. 5A, lanes
1 and 3). In the pp717-1285 sample, another protein of
~51 kDa was clearly detectable. This protein was not identified in
the pp717-1285_C1054A translation reaction (Fig. 5A,
compare lanes 1 and 2 with lanes 3 and
4). The 51-kDa protein was detectable as early as 40 min
after translation initiation and became increasingly prominent after
translation termination and further incubation of the translation
products for 120 min at 30 °C (Fig. 5A, lanes 1 and
2). The data suggest that the 51-kDa protein may represent a
processing product of pp717-1285, and the size of the protein is
consistent with the expected size of the C-terminal pp717-1285 processing product if cleavage occurred at
Gly897 Gly898. Subsequently, also the
N-terminal processing product of pp717-1285 was identified (see Fig.
7A). Taken together, we concluded from this experiment that
PL1pro can cleave the Gly897 Gly898 bond or a
nearby site.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 5.
Evidence for a second PL1pro cleavage site in
the HCoV pp1a and pp1ab polyproteins. A, in
vitro translation reactions of capped RNAs derived from
EcoRI-linearized plasmids pBST-111-103 and
pBST-111-103_C1054A. The respective RNAs encode the pp1a/1ab amino
acids 717-1285 (WT, lanes 1 and 2) or the same
sequence with an active-site replacement of the catalytic
Cys1054 (C1054A, lanes 3 and 4). The
translation reactions were done as described under "Experimental
Procedures," and the reaction products were either analyzed directly
(lanes 1 and 3) or after further incubation for
120 min (lanes 2 and 4). The positions of
full-length precursor proteins and cleavage products are indicated.
B, a protein called pp717-1285_VM was translated in a
reticulocyte lysate in the presence of [35S]methionine.
Except for three amino acid substitutions (V900M, V906M, and V908M),
which had been introduced downstream to the presumed cleavage site,
this protein contained the HCoV pp1a/1ab wild-type sequence from
residues 717 to 1285. The translation reaction was incubated for 160 min at 30 °C, and the reaction products were separated on an
SDS-12.5% polyacrylamide gel. After electrophoretic transfer to PVDF
membranes, the position of the C-terminal cleavage product was
determined by autoradiography. The isolated protein was subjected to 16 cycles of Edman degradation, and the distribution of radiolabeled amino acids was determined by scintillation
counting. The amino acid sequence of pp1a and pp1ab from positions 895 to 913 is shown. The amino acids Met900,
Met906, and Met908 present in pp717-1285_VM
are shown in boldface type, and the newly identified PL1pro
cleavage site is indicated by an arrow.
|
|
As the sequence alignment in Fig. 3 shows, the predicted HCoV
p87 p195/p210 cleavage site, Gly897 Gly898,
is preceded by two alanine residues and is not well conserved in other
coronaviruses. Thus, alternative assignments of the scissile bond
within the Ala-Ala-Gly-Gly sequence, which would be compatible with our
current understanding of the coronavirus PLpro substrate specificities
and the results of the above experiment, could not be ruled out.
Consequently, an N-terminal radiosequence of the C-terminal cleavage
product was performed to determine the scissile bond precisely. Because
the predicted N-terminal Gly898 is immediately followed by
three Val residues at positions 900, 906, and 908, we initially
attempted, by using either [3H]valine or
[14C]valine in the translation reactions, to incorporate
radiolabel into pp717-1285. However, these efforts failed to
incorporate sufficient label for radiosequence analyses, and therefore,
we decided to analyze a cleavage product in which these three Val residues were replaced with Met (V900M, V906M, and V908M). In vitro synthesis of the mutated precursor, pp717-1285_VM, in the presence of [35S]methionine revealed that the Met-for-Val
substitutions were compatible with PL1pro-mediated autoprocessing (data
not shown), and thus, we were able to isolate a sufficiently labeled
C-terminal cleavage product. The data we obtained in the subsequent
sequence analysis conclusively showed that the PL1pro-mediated cleavage occurs at the Gly897 Gly898 peptide bond
(Fig. 5B), confirming our previous prediction.
HCoV PL2pro Can Cleave the Conserved Site at the Predicted
p87 p195/p210 Junction--
To address a possible role of PL2pro in
the cleavage of the Gly897 Gly898 bond, two
pp717-1910 mutants, which contained PL1pro and PL2pro, were
characterized. In the first mutant, pp717-1910_C1054A, the PL1pro
active-site nucleophile, Cys1054, was replaced with Ala.
This substitution completely inactivated the HCoV PL1pro activity
toward the p9 p87 (25) and p87 p195/p210 (Fig. 5A)
junctions. Surprisingly, we found that the pp717-1910_C1054A protein
was as efficiently processed as its wild-type parent pp717-1910. Both
precursors were cleaved to produce proteins with apparent molecular
masses of ~120 kDa (Fig. 6A,
lanes 1-4). This result indicated that another
(non-PL1pro-mediated) activity may be responsible for cleavage of the
pp717-1910_C1054A protein at the p87 p195/p210 junction. To verify
that PL2pro is the protease that mediates this cleavage, the double
mutant pp717-1910_C1054A/W1702L was analyzed. In this mutant, both the
PL1pro and PL2pro domains were inactivated by active-site replacements:
PL1pro by a replacement of the active-site nucleophile
Cys1054 with Ala, and PL2pro by a Leu substitution for the
highly conserved Trp1702, which is immediately adjacent to
the active-site nucleophile Cys1701. The mutated protein
proved to be proteolytically inactive (Fig. 6A, lanes 5 and
6), confirming that the observed cleavage is indeed associated with the activity of PL2pro.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 6.
Proteolytic activity of the PL2pro domain and
identification of its cleavage site. A, the HCoV
ORF1a-encoded amino acids 717-1910 were translated in rabbit
reticulocyte lysates in the presence of [35S]methionine.
The proteins to be tested for proteolytic activity contained wild-type
sequence (lanes 1 and 2) or the same sequence
with active-site replacements in PL1pro (C1054A, lanes 3 and
4) and both PL1pro and PL2pro (C1054A and W1702L),
respectively. The proteins were translated at 30 °C for 40 min, and
after the termination of translation, the reaction products were either
analyzed directly (lanes 1, 3, and 5) or after
further incubation for 120 min (lanes 2, 4, and
6). The analysis was done by SDS-polyacrylamide gel
electrophoresis in a 10-17% polyacrylamide gradient gel. The
positions of full-length precursor proteins and cleavage products are
indicated. B, a protein called pp717-1910_C1054A-VM was
translated in a reticulocyte lysate in the presence of
[35S]methionine. Except for a PL1pro-inactivating amino
acid replacement (C1054A) and three additional substitutions (V900M,
V906M, and V908M), which had been introduced downstream to the
predicted cleavage site, this protein contained the HCoV pp1a/1ab
wild-type sequence from residues 717 to 1910. The translation reaction
was incubated for 160 min at 30 °C, and the reaction products were
separated on an SDS-10% polyacrylamide gel. After electro- phoretic transfer to PVDF membranes, the position of the
C-terminal cleavage product was determined by autoradiography. The
isolated protein was subjected to 16 cycles of Edman degradation, and
the distribution of radiolabeled amino acids was determined by
scintillation counting. The amino acid sequence of pp1a and pp1ab from
positions 895 to 913 is shown. The amino acids Met900,
Met906, and Met908 present in
pp717-1910_C1054A-VM are shown in boldface type, and the
deduced PL2pro cleavage site is indicated by an arrow.
|
|
Based on the data described above, it was reasonable to believe that
PL2pro, like PL1pro, cleaves the (same)
Gly897-Gly898 bond. Alternatively, PL1pro and
PL2pro might use partly overlapping sites (for example, in the
Ala895-Ala-Gly-Gly898 sequence) or the two
proteases might cleave separate but adjacent sites in the viral
polyprotein. To establish the specificity of PL2pro unequivocally, we
determined the newly identified HCoV PL2pro cleavage site by protein
sequencing, using the same approach as described above for the
determination of the PL1pro cleavage site structure. We produced a
[35S]methionine-labeled derivative of pp717-1910_C1054A,
in which each of the Val900, Val906, and
Val908 residues was replaced with Met
(pp717-1910_C1054A-VM). These replacements did not affect the
PL2pro-mediated processing pattern of the primary translation product
(data not shown). The radiosequence analysis of the C-terminal
pp717-1910_C1054A-VM processing product revealed that PL2pro cleaves
the pp1a/pp1ab Gly897 Gly898 peptide bond
(Fig. 6B). Hence, our combined data show that the HCoV
PL1pro and PL2pro domains cleave the same site in the viral polyprotein
in vitro.
PL2pro Dominates Over PL1pro in the Cleavage of the
Gly897-Gly898 Peptide Bond--
The above
findings imply that, by cleavage of the same site, both PL1pro and
PL2pro are able to mediate the autoproteolytic release of the protein
of which they are part. To gain initial insight into how these
activities might be coordinated, the effects of the individual domains
in the PL1pro-X-PL2pro constellation on the efficiency of the
Gly897 Gly898 cleavage were analyzed.
We initially investigated how the X domain or the combination of X and
PL2pro affect the PL1pro-mediated cleavage at the p87 p195/p210 junction. The data shown in Fig.
7A indicate that, irrespective of whether or not the X domain was present, the PL1pro-mediated cleavage progressed slowly, that is even after 160 min, significant amounts of the pp717-1285 and pp717-1436 primary translation products remained uncleaved (Fig. 7A, lanes 2 and 4). In
contrast, the C-terminally extended pp717-1910 and pp759-1910
proteins, which both contained PL1pro, X, and PL2pro, were
(almost) completely cleaved after the same incubation time (Fig.
7A, lanes 6 and 8). This observation suggests
that either (i) PL1pro and PL2pro act in concert or (ii) PL2pro takes
over the activity toward the Gly897 Gly898
site from PL1pro to cleave this site more rapidly, which then leads to
nearly complete substrate conversion within the given period.

View larger version (56K):
[in this window]
[in a new window]
|
Fig. 7.
Relationship between PL1pro and
PL2pro proteolytic activities. A, in vitro
translation reactions of capped RNAs encoding the pp1a/1ab amino acids
717-1285 (lanes 1 and 2), amino acids 717-1436
(lanes 3 and 4), amino acids 717-1910
(lanes 5 and 6), and amino acids 759-1910
(lanes 7 and 8). The proteins to be tested for
proteolytic activity were translated in rabbit reticulocyte lysates in
the presence of [35S]methionine at 30 °C for 40 min.
After the termination of translation, the reaction products were either
analyzed directly (lanes 1, 3, 5, and 7) or after
further incubation for 120 min (lanes 2, 4, 6, and
8). The analysis was done by SDS-polyacrylamide gel
electrophoresis in a 10-17% polyacrylamide gradient gel. Full-length
precursor proteins and major processing products are indicated (*,
precursor protein; , processing product). Also, the calculated
cleavage activities of the full-length precursor proteins are given
(see "Experimental Procedures" for details). B,
proteolytic activities of pp717-1910-derived proteins carrying
active-site mutations in the two HCoV PLpro domains. The proteins to be
tested for proteolytic activity were translated in rabbit reticulocyte
lysates in the presence of [35S]methionine at 30 °C
for 40 min. After termination of translation, the reaction products
were separated by SDS-polyacrylamide gel electrophoresis. They were
either analyzed directly (lanes 1, 3, 5, 7, and
9) or after further incubation for 120 min (lanes 2, 4, 6, 8, and 10). The proteins, which all encompassed
the HCoV pp1a/pp1ab amino acids 717-1910, contained Cys-to-Ala
replacements of the putative nucleophilic residues of PL1pro (C1054A,
lanes 1 and 2) and PL2pro (C1701A, lanes
5 and 6), 8-amino acid deletions including the putative
nucleophilic residues of PL1pro ( 1054-1061, lanes 3 and
4) and PL2pro ( 1701-1708, lanes 7 and
8) or wild-type sequence (lanes 9 and
10). The positions of full-length precursor proteins and
cleavage products are indicated. Also the calculated cleavage
activities of the full-length precursor proteins are given.
|
|
To address the latter issue, we characterized a series of pp717-1910
derivatives in which either PL1pro or PL2pro was selectively inactivated. As shown in Fig.
7B (lanes 1-4),
inactivation of the proteolytic activity of PL1pro (either by
substitution of the catalytic Cys residue alone (pp759-1910_C1054A) or
by deletion of the highly conserved predicted -helix of which the
Cys nucleophile is part (pp759-1910_ 1054-1061)) did not
significantly affect the processing at the
Gly897 Gly898 site. In contrast, the
analogous PL2pro mutants (pp759-1910_C1701A; pp759-1910_ 1701-1708) were markedly inhibited in the cleavage of
the same bond (Fig. 7B, lanes 5-8). Importantly, the
Gly897 Gly898 site cleavage by PL1pro was
more pronounced in the absence rather than in the presence of the
inactivated PL2pro (compare Fig. 7A, lanes 1-4, to Fig.
7B, lanes 5-8). The combined results presented in Fig. 7
indicate that (i) PL2pro cleaves the
Gly897 Gly898 site more efficiently than
PL1pro and (ii) PL2pro suppresses the PL1pro proteolytic activity.
Since the active-site deletion mutant of PL2pro retained the
dominant-negative effect on PL1pro, it is not likely that PL2pro simply
outcompetes PL1pro for the cleavage site. Further experiments need to
be performed to elucidate the details of this mechanism.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 8.
Phylogenetic relationships among
coronavirus PLpros. A, expected, and B,
reconstructed and unrooted trees for coronavirus PLpros. The genetic
groups recognized in coronaviruses are uniquely colored. A,
the topology of this tree of PLpros was approximated on the basis of
sequence comparisons of other coronavirus replicative
enzymes3 that result in a tree topology identical to the
one shown here for the PL1pro and PL2pro subgroups. This representation
is called the "expected" tree. The two lineages that were
reshuffled in B, MHVA/BCoVL_PL2 and TGEV/HCoV_PL1, are shown
with a gray background. B, the
"reconstructed" tree was generated using an alignment of PLpros
(Fig. 3; see also Fig. 2A in (32)) and the NJ algorithm with
the Kimura correction as implemented in the ClustalX program. The
alignment included the following sequences: HCoV_PL1pro (1043-1227),
HCoV_PL2pro (1690-1885), TGEV_PL1pro (1082-1266), TGEV_PL2pro
(1577-1763), MHVA_PL1 (1110-1292), MHVA_PL2 (1705-1896), BCoVL_PL1
(1063-1245), BCoVL_PL2 (1660-1851) and IBV_PL2 (1263-1457). BCoVL is
from Footnote 3; for the sources of the other sequences see Fig. 3. The
number of trees, in which a particular bifurcation was sustained in the
course of 1000 bootstrap simulations, is given at each node.
|
|
The Partial Substrate Redundancy Is Accompanied by Parallel
Evolution of the Paralogous PLpros--
The ubiquitous occurrence of
PL1pro and PL2pro in all coronaviruses sequenced to date (Fig.
3)3 indicates that these
enzymes most probably originated from the duplication of a papain-like
protease in one of the ancestors of the contemporary coronaviruses.
PL1pro and PL2pro have subsequently evolved as part of the pp1a/pp1ab
polyproteins that automatically determines the branching of their
phylogeny (Fig. 8A). However, when the radial tree was
reconstructed using a multiple alignment of coronavirus PLpros, its
topology markedly deviated from the one determined for other
replicative proteins (compare Fig. 8, A and B).
Only the orthologous enzymes of the most closely related viruses, TGEV
and HCoV, and MHV and bovine coronavirus (BCoVL), respectively, were
clustered together (Fig. 8B). More deeply rooted branches of
PL1pro and PL2pro proteins were interleaved (Fig. 8B) rather
than forming two separate divisions, one for PL1pros and another for
PL2pros (Fig. 8A). The tree topology of Fig. 8B was inferred using an NJ algorithm (42). It was supported by results of
a bootstrap analysis (Fig. 8B) and was also observed in one
of the five most parsimonious trees with the best score after an
exhaustive search of the entire tree-space using PAUP*4.0.0d55 (44).
The four other most parsimonious trees also deviated from the expected
tree presented in Fig. 8A (data not shown). These observations indicate that either our initial assumption of the one-time duplication of a PLpro domain in the coronavirus ancestral lineage is not correct or the evolution of the paralogous PLpros was
complicated by homoplasy events that fooled the reconstruction of the
genuine topology presented in Fig. 8A. Remarkably, in the inferred PLpro tree shown in Fig. 8B, the PLpros cluster
according to the coronavirus genetic grouping (53), bringing together the paralogous enzymes of the same virus (Fig. 8B). This
topology makes the second evolutionary scenario most probable as it is compatible with a parallel evolution of the paralogous PL1pro and
PL2pro under the pressure of the common substrate that these proteases
cleave in HCoV and in other coronaviruses. Thus, the phylogenetic analysis of PLpros supports the results of other analyses
(see above) and indicates that the substrate pressure had a significant
impact on the structure of the coronavirus PLpros.
 |
DISCUSSION |
The life cycle of many RNA viruses is driven by the concerted
action of several proteases. The proteolytic enzymes mediate the
production of diverse functional subunits and thus couple (and
regulate) the replication, expression, and encapsidation of the virus
genome in a timely and spatially coordinated manner. To do this,
proteases cleave non-overlapping sets of few sites in the virus-encoded
polyprotein(s) (1-3). In this study, we have characterized two
sequentially positioned and paralogous proteases of a human coronavirus
with an unusual structural organization featuring a Zn2+
finger embedded between the two domains of a papain-like fold (32). We
now show that these proteases also possess unique functional properties
as they have overlapping substrate specificities. The coordination of
these protease activities may require an extent of complexity not
observed elsewhere.
PL2pro Is the Dominant Force and PL1pro Is Tightly Regulated to
Release p195/p210 in Coronaviruses--
To gain insight into the
autocatalytic release mechanisms of the largest coronavirus replicative
protein, p195/p210, from its polyprotein precursor, we updated a
coronavirus-wide multiple alignment of this protein. The results we
obtained revealed that p195/p210 has a conserved domain organization
and is flanked by conserved cleavage sites. Furthermore, IBV (like
other coronaviruses) is predicted to have two PLpro domains (rather
than only one PLpro as thought before). The previously characterized
IBV papain-like protease, known as PLpro, was shown to be an ortholog
of the coronavirus PL2pro domains, and an inactivated remnant of PL1pro
was identified at a more upstream position in the viral polyprotein. We
then sought to connect the revised domain organization of p195/p210 with the available experimental data and found that, strikingly, the
processing mechanisms at the N terminus of p195/p210 vary among
different coronaviruses. Thus, it emerged that the conserved peptide
bond at the N terminus of p195/p210 is cleaved by different proteases
in two coronaviruses, by PL1pro in MHV (20) but by PL2pro in IBV (15). Furthermore, this bond was apparently
not cleaved by PL1pro in vitro in HCoV (25). We attempted to
reconcile the results of our theoretical analysis and the published
data and, to this end, performed a comprehensive characterization of this cleavage reaction in HCoV. By using in vitro
translation of synthetic RNAs in reticulocyte lysates, it was
established that both PL1pro and PL2pro cleave the predicted
Gly897 Gly898 bond at the N terminus of
p195/p210. Although p195/p210 itself remains to be identified in
HCoV-infected cells, its upstream neighbor in the polyprotein, p87,
which is released by cleavage of the same bond, was detected in this
study. This result strongly suggests that our observations do not
reflect an in vitro artifact.
We then characterized mutants of PL1pro and PL2pro and found specific
conditions under which the proteolytic activities of PL1pro and PL2pro,
respectively, were evident. In a precursor containing PL1pro but
lacking PL2pro, the p195/p210 N-terminal cleavage was mediated by
PL1pro. If the HCoV PL1pro was expressed in combination with PL2pro
from the same RNA template, the N-terminal cleavage of p195/p210 was
significantly stimulated (Fig. 7A). Both results are
consistent with similar phenomena reported recently for MHV
trans-cleavage assays (50) (see below). Subsequently, a more detailed
analysis of the enhancement of the HCoV PL2pro activity led us to
conclude that PL2pro is able to cleave the p195/p210 site on its own.
Moreover, it became evident that PL2pro is capable of silencing the
PL1pro activity. These conclusions were not reached in a similar study
of MHV (50), which failed to positively identify the proteolytic
activity of PL2pro. We believe that the apparent discrepancy between
the HCoV and MHV data results from technical reasons and does not
reflect virus-specific differences in the p195/p210 processing mechanism.
Thus, in the MHV study, the proteolytic activities of proteins
containing both the PL1pro and PL2pro domains were demonstrated in
respect to the equivalents of the p9 p87 and p87 p195/p210 sites in
bimolecular reactions. Furthermore, the design of these previously tested proteins differed from that of the proteins characterized in our study in monomolecular reactions. Teng
et al. (50) observed a significant stimulation of the
cleavages in the presence of PL2pro, and in a separate experiment (Fig. 7A in (50)), the cleavages were blocked in a nonconservative (His-to-Pro) PL1pro active-site mutant. Although the latter result was
interpreted (50) to argue against an involvement of PL2pro in the
cleavage, we consider this conclusion premature since no data on the
corresponding PL2pro active-site mutant(s) were presented in that
paper. Likewise, in two MHV mutants in which PL1pro was deleted, the C
terminus of the deletion was placed downstream of Block C, that is
within the predicted N-terminal region of PL2pro (see Fig.
3). As a result, PL2pro was unintentionally truncated, which, according
to our model of p195/p210, predetermined the processing-negative
phenotype of those mutants. The ability of PL1pro and PL2pro to cleave
the p87 p195/p210 junction in trans has yet to be
characterized for HCoV.
The results discussed above and the other published data (20, 25, 32)
suggest that the PL1pro activity at the N terminus of p195/p210 is
tightly down-regulated by upstream and downstream domains in both MHV
and HCoV. Regardless of the mechanisms of these effects, which remain
to be elucidated, these observations indicate that PL1pro may have a
very short time frame to exert its proteolytic activity in
cis. We therefore suggest that PL2pro releases the N
terminus of the p195/p210 proteins in HCoV and other coronaviruses and
dominates over PL1pro in this cleavage reaction (Fig.
9), although we acknowledge that the
PL2pro activity at this site remains to be formally proved for MHV (and
some other coronaviruses). In contrast, the processing at the p195/p210
C terminus may be mediated by PL2pro alone (Fig. 9). This site was shown to be effectively processed by PL2pro in IBV (16) and MHV (22),
although the ability of PL1pro to cleave this site was not yet
rigorously tested for any coronavirus. Future studies on the
p195/p210 C-terminal cleavage site structure should also resolve
a slight uncertainty of our computer-assisted prediction, which was due
to the low complexity and weak conservation in this region, about the
precise location of the scissile bond (Fig. 3). This advance would
allow us to correlate the structure of the three cleavage sites with
the type of the cognate protease(s) in the N-terminal part of the
coronavirus pp1a/pp1ab proteins (Fig. 9).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 9.
Proposed scheme for the proteolytic
processing of coronavirus replicative polyproteins by the accessory
proteases PL1pro and PL2pro. Cleavage sites (P1 and P1' residues
indicated) identified in the pp1a/pp1ab proteins of IBV, MHV, HCoV, and
TGEV and the corresponding processing products identified in
virus-infected cells are shown. Putative cleavage sites, which are
predicted on the basis of the results of the present study, are
indicated by ?. Also, the protease domains responsible for
specific cleavages are given, with solid lines indicating
experimentally characterized cleavages and dotted lines
indicating predicted cleavages. The proteolytically inactive IBV PL1pro
is marked by a black background color. For other
abbreviations see Figs. 1B and 3.
|
|
The characterization of the HCoV p87 p195/p210 cleavage in
vitro proved to be a significant technical challenge, since
template DNAs containing the "non-clonable" PL2pro coding sequence
had to be produced. In vitro ligation and PCR approaches
(combined with extensive nucleotide sequencing) finally allowed us to
analyze the processing of large size precursors containing both HCoV
papain-like proteases. The spectrum of constructs (Fig. 2) allowed us
to discriminate between the activities of PL1pro and PL2pro. However,
more experiments are yet to be done to address a possible involvement
of other conserved and non-conserved domains of p195/p210 as well as
other replicative proteins in the modulation of the PL1pro and PL2pro activities. Also, since the cellular environment may be involved in the
control of specific proteolytic activities, future studies of the
p195/p210 autoprocessing in the natural setting using reverse genetics
are required to understand the full complexity of these processes.
Also, these studies might reveal variations among coronaviruses.
Evolution of PL1pro and PL2pro and Their Substrates in
Coronaviruses--
The PL1pro-inactive/PL2pro-active organization of
IBV was imitated in two of the HCoV mutants (pp717-1910_C1054A;
pp717-1910_ 1054-1061) tested in this study (Fig. 7B).
Remarkably, the mutated precursors were processed in an IBV-like (that
is PL2pro-controlled) fashion. This result connects IBV with other
coronaviruses that have two active PLpros. It allows us to reconstruct
a plausible scenario of the evolutionary events that might have led to
the present day diversity of the N-terminal region of the coronavirus
replicative polyproteins. We speculate that an immediate ancestor of
the contemporary coronaviruses already encoded a pair of PLpros. It is
likely that PL2pro, probably assisted by PL1pro, mediated the p195/p210
autoprocessing, whereas PL1pro could have been responsible for the
release of the small N-terminal protein. (It should be noted that the
ability of PL2pro to release the N-terminal protein has not been tested rigorously in coronaviruses with two active PLpros.) Three coronavirus lineages, known as group 1 (prototyped by HCoV), group 2 (prototyped by
MHV), and group 3 (prototyped by IBV), have evolved from the common
coronavirus ancestor (53).3 The individual lineages display
a considerable sequence variability that also includes the N terminus
of the replicative polyproteins (Fig. 9). Groups 1 and 2 encode very
specific (and possibly unrelated) versions of the N-terminal protein,
p28 in MHV and p9 in HCoV, that significantly differ in size. The
activities of these proteins are unknown but, because of their unique
structural characteristics, they must be lineage-specific. The IBV
lineage does not encode a counterpart to the N-terminal proteins of
other coronaviruses (Fig. 9); most likely, it was deleted or, after
fusion with the upstream protein, diverged beyond recognition. In the
absence of its major substrate, the proteolytic activity of PL1pro was no longer essential for the IBV ancestor and, as a result, PL1pro was
inactivated by accumulating mutations. Since the IBV PL1pro was not
deleted, it must possess another (nonproteolytic) activity, which
remains to be determined.
The PL1pro and PL2pro domains of coronaviruses have probably evolved by
the duplication of an ancestral papain-like protease. Since then, they
have diverged substantially and share less than ~25% of identical
residues in every coronavirus pair. The evolution of paralogous
proteases is commonly driven by the need to process novel substrates.
There are numerous paralogous proteases with different specificities
among cellular enzymes; and the entero-/rhinovirus 2A and 3C proteases,
employing similar chymotrypsin-like folds and recognizing different
sites, illustrate this trend in viruses (reviewed in Refs. 3 and 54).
Surprisingly, PL1pro and PL2pro of HCoV (and presumably other
coronaviruses) retained overlapping substrate specificities despite a
profound divergent evolution elsewhere in the genome. This conservation
involves yet-to-be-identified determinants in PL1pro and PL2pro,
although it can already be noted that all proteolytically active
coronavirus PLpros share a unique zinc finger that was shown to be
essential for the proteolytic activity of the HCoV PL1pro (32). The
PL1pro and PL2pro alignments (Fig. 3) revealed that only few positions
are occupied by lineage-specific amino acid
residues,4 and this unusual
pattern could be linked to the selective pressure of a common
substrate, driving the parallel evolution of PL1pro and PL2pro.
Accordingly, the expected topology of the coronavirus PLpro tree (Fig.
8A) was not readily reconstructed using the conventional algorithms (Fig. 8B).
p195/p210 Is a Multifunctional Protein with a Unique Regulation of
Expression--
The cleavage of the same site by two proteases may
provide a specific selective advantage since it creates an additional
level of regulation in processes that involve (and consume) p195/p210. The unique character of this regulation might be dictated by the exceptional complexity of the domain organization of p195/p210. It is
conceivable that the p195/p210 processing may have different kinetics
if either PL1pro/PL2pro or PL2pro alone mediates this reaction. Kinetic
parameters could affect the localization of specific products in the
cell and/or their interactions with other partners. The p195/p210
product may be anchored in membranes through hydrophobic regions of the
C-terminal Y domain or other mechanisms (55) and, furthermore, may be
involved in the regulation of transcription through the
PLpro-associated zinc finger domains. Finally, the fact that field
isolates of BCoV obtained from two different tissues of the same animal
were recently shown to selectively accumulate non-synonymous mutations
in the p195/p210 protein3 points to yet another functional
aspect of this multidomain protein. Taken together, these data suggest
that the above-mentioned or other activities of this multifunctional
protein may have profound effects on the host cell or even the entire
organism. It is thus tempting to speculate that the sophisticated
two-protease regulation at the N terminus of p195/p210 might be
involved in specific coronavirus-host interactions.
 |
ACKNOWLEDGEMENTS |
We are grateful to V. Chouljenko and K. Kousoulas for access to the BCoVL sequence and permission to
cite unpublished observations. We also thank V. Hoppe for protein
sequence data and the staff of the Advanced Biomedical Computing Center
for the assistance with computer resources.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Supported by Deutsche Forschungsgemeinschaft Grants SI 357/2-2, ZI
618/2-1, and ZI 618/2-2. To whom correspondence may be addressed. Tel.:
49-931-2013966; Fax: 49-931-2013934; E-mail: ziebuhr@vim.uni-
wuerzburg.de.
Supported by Grant NO1-CO-56000 from the NCI, National
Institutes of Health. To whom correspondence may be addressed: Advanced Biomedical Computing Center, 430 Miller Dr., Rm. 228, SAIC/NCI-Frederick, Frederick, MD 21702-1201. Tel.: 301-846-1991; Fax:
301-846-5762; E-mail: gorbalen@ncifcrf.gov.
Published, JBC Papers in Press, June 28, 2001, DOI 10.1074/jbc.M104097200
2
V. Thiel, unpublished observations.
3
Chouljenko, V. N., Lin, X. Q., Storz, J.,
Kousoulas, K. G., and Gorbalenya, A. E. (2001) J. Gen. Virol.
82, in press.
4
J. Ziebuhr, V. Thiel, and A. E. Gorbalenya, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
HCoV, human
coronavirus 229E;
sg, subgenomic;
BCoV, bovine coronavirus;
IBV, avian
infectious bronchitis virus;
MHV, murine hepatitis virus;
TGEV, porcine
transmissible gastroenteritis virus;
MBP, maltose-binding protein;
NJ, neighbor-joining;
ORF, open reading frame;
PLpro, papain-like protease;
PVDF, polyvinylidene difluoride;
PCR, polymerase chain reaction.
 |
REFERENCES |
| 1.
|
Kräusslich, H. G.,
and Wimmer, E.
(1988)
Annu. Rev. Biochem.
57,
701-754
|
| 2.
|
Dougherty, W. G.,
and Semler, B. L.
(1993)
Microbiol. Rev.
57,
781-822
|
| 3.
|
Gorbalenya, A. E.,
and Snijder, E. J.
(1996)
Perspect. Drug Discov. Des.
6,
64-86
|
| 4.
|
den Boon, J. A.,
Snijder, E. J.,
Chirnside, E. D.,
de Vries, A. A.,
Horzinek, M. C.,
and Spaan, W. J.
(1991)
J. Virol.
65,
2910-2920
|
| 5.
|
Cavanagh, D.
(1997)
Arch. Virol.
142,
629-633
|
| 6.
|
Lai, M. M. C.,
and Cavanagh, D.
(1997)
Adv. Virus Res.
48,
1-100
|
| 7.
|
Molenkamp, R.,
van Tol, H.,
Rozier, B. C.,
van der Meer, Y.,
Spaan, W. J.,
and Snijder, E. J.
(2000)
J. Gen. Virol.
81,
2491-2496
|
| 8.
|
Thiel, V.,
Herold, J.,
Schelle, B.,
and Siddell, S. G.
(2001)
J. Virol.
75,
6676-6681
|
| 9.
|
Seybert, A.,
van Dinten, L. C.,
Snijder, E. J.,
and Ziebuhr, J.
(2000)
J. Virol.
74,
9586-9593
|
| 10.
|
Seybert, A.,
Hegyi, A.,
Siddell, S. G.,
and Ziebuhr, J.
(2000)
RNA
6,
1056-1068
|
| 11.
|
Brierley, I.,
Boursnell, M. E.,
Binns, M. M.,
Bilimoria, B.,
Blok, V. C.,
Brown, T. D.,
and Inglis, S. C.
(1987)
EMBO J.
6,
3779-3785
|
| 12.
|
Ziebuhr, J.,
Snijder, E. J.,
and Gorbalenya, A. E.
(2000)
J. Gen. Virol.
81,
853-879
|
| 13.
|
Gorbalenya, A. E.,
Koonin, E. V.,
and Lai, M. M. C.
(1991)
FEBS Lett.
288,
201-205
|
| 14.
|
Lee, H. J.,
Shieh, C. K.,
Gorbalenya, A. E.,
Koonin, E. V.,
La Monica, N.,
Tuler, J.,
Bagdzhadzhyan, A.,
and Lai, M. M.
(1991)
Virology
180,
567-582
|
| 15.
|
Lim, K. P.,
and Liu, D. X.
(1998)
Virology
245,
303-312
|
| 16.
|
Lim, K. P.,
Ng, L. F.,
and Liu, D. X.
(2000)
J. Virol.
74,
1674-1685
|
| 17.
|
Denison, M.,
and Perlman, S.
(1987)
Virology
157,
565-568
|
| 18.
|
Denison, M. R.,
Hughes, S. A.,
and Weiss, S. R.
(1995)
Virology
207,
316-320
|
| 19.
|
Schiller, J. J.,
Kanjanahaluethai, A.,
and Baker, S. C.
(1998)
Virology
242,
288-302
|
| 20.
|
Bonilla, P. J.,
Hughes, S. A.,
Piñón, J. D.,
and Weiss, S. R.
(1995)
Virology
209,
489-497
|
| 21.
|
Bonilla, P. J.,
Hughes, S. A.,
and Weiss, S. R.
(1997)
J. Virol.
71,
900-909
|
| 22.
|
Kanjanahaluethai, A.,
and Baker, S. C.
(2000)
J. Virol.
74,
7911-7921
|
| 23.
|
Baker, S. C.,
Shieh, C. K.,
Soe, L. H.,
Chang, M. F.,
Vannier, D. M.,
and Lai, M. M.
(1989)
J. Virol.
63,
3693-3699
|
| 24.
|
Baker, S. C.,
Yokomori, K.,
Dong, S.,
Carlisle, R.,
Gorbalenya, A. E.,
Koonin, E. V.,
and Lai, M. M.
(1993)
J. Virol.
67,
6056-6063
|
| 25.
|
Herold, J.,
Gorbalenya, A. E.,
Thiel, V.,
Schelle, B.,
and Siddell, S. G.
(1998)
J. Virol.
72,
910-918
|
| 26.
|
Dong, S.,
and Baker, S. C.
(1994)
Virology
204,
541-549
|
| 27.
|
Hughes, S. A.,
Bonilla, P. J.,
and Weiss, S. R.
(1995)
J. Virol.
69,
809-813
|
| 28.
|
Almazan, F.,
González, J. M.,
Pénzes, Z.,
Izeta, A.,
Calvo, E.,
Plana-Durán, J.,
and Enjuanes, L.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
5516-5521
|
| 29.
|
Yount, B.,
Curtis, K. M.,
and Baric, R. S.
(2000)
J. Virol.
74,
10600-10611
|
| 30.
|
Thiel, V.,
Herold, J.,
Schelle, B.,
and Siddell, S. G.
(2001)
J. Gen. Virol.
82,
1273-1281
|
| 31.
|
LaStarza, M. W.,
Lemm, J. A.,
and Rice, C. M.
(1994)
J. Virol.
68,
5781-5791
|
| 32.
|
Herold, J.,
Siddell, S. G.,
and Gorbalenya, A. E.
(1999)
J. Biol. Chem.
274,
14918-14925
|
| 33.
|
Tijms, M. A.,
van Dinten, L. C.,
Gorbalenya, A. E.,
and Snijder, E. J.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
1889-1894
|
| 34.
|
Thompson, J. D.,
Gibson, T. J.,
Plewniak, F.,
Jeanmougin, F.,
and Higgins, D. G.
(1997)
Nucleic Acids Res.
25,
4876-4882
|
| 35.
|
Morgenstern, B.
(1999)
Bioinformatics
15,
211-218
|
| 36.
|
Schuler, G. D.,
Altschul, S. F.,
and Lipman, D. J.
(1991)
Proteins
9,
180-190
|
| 37.
|
Altschul, S. F.,
Madden, T. L.,
Schaffer, A. A.,
Zhang, J.,
Zhang, Z.,
Miller, W.,
and Lipman, D. J.
(1997)
Nucleic Acids Res.
25,
3389-3402
|
| 38.
|
Eddy, S. R.
(1996)
Curr. Opin. Struct. Biol.
6,
361-365
|
| 39.
|
Henikoff, S.,
and Henikoff, J. G.
(1994)
J. Mol. Biol.
243,
574-578
|
| 40.
|
Rost, B.,
Casadio, R.,
Fariselli, P.,
and Sander, C.
(1995)
Protein Sci.
4,
521-533
|
| 41.
|
Rost, B.
(1996)
Methods Enzymol.
266,
525-539
|
| 42.
|
Saitou, N.,
and Nei, M.
(1987)
Mol. Biol. Evol.
4,
406-425
|
| 43.
|
Kimura, M.
(1983)
The Neutral Theory of Molecular Evolution
, p. 367, Cambridge University Press, Cambridge, NY
|
| 44.
|
Swofford, D. L.
(2000)
PAUP* Phylogenetic Analysis Using Parsimony, Version 4
, Sinauer Associates, Inc., Sunderland, MA
|
| 45.
|
Page, R. D.
(1996)
Comput. Appl. Biosci.
12,
357-358
|
| 46.
|
Ziebuhr, J.,
Herold, J.,
and Siddell, S. G.
(1995)
J. Virol.
69,
4331-4338
|
| 47.
|
Herold, J.,
Raabe, T.,
Schelle-Prinz, B.,
and Siddell, S. G.
(1993)
Virology
195,
680-691
|
| 48.
|
Herold, J.,
Siddell, S. G.,
and Ziebuhr, J.
(1996)
Methods Enzymol.
275,
68-89
|
| 49.
|
Ziebuhr, J.,
and Siddell, S. G.
(1999)
J. Virol.
73,
177-185
|
| 50.
|
Teng, H.,
Piñón, J. D.,
and Weiss, S. R.
(1999)
J. Virol.
73,
2658-2666
|
| 51.
|
Grötzinger, C.,
Heusipp, G.,
Ziebuhr, J.,
Harms, U.,
Süss, J.,
and Siddell, S. G.
(1996)
Virology
222,
227-235
|
| 52.
|
Yao, Z.,
Jones, D. H.,
and Grose, C.
(1992)
PCR Methods Appl.
1,
205-207
|
| 53.
|
Siddell, S. G.
(1995)
in
The Coronaviridae
(Siddell, S. G., ed)
, pp. 1-10, Plenum Press, New York
|
| 54.
|
Ryan, M. D.,
and Flint, M.
(1997)
J. Gen. Virol.
78,
699-723
|
| 55.
|
Bi, W.,
Piñón, J. D.,
Hughes, S.,
Bonilla, P. J.,
Holmes, K. V.,
Weiss, S. R.,
and Leibowitz, J. L.
(1998)
J. Neurovirol.
4,
594-605
|
| 56.
|
Gorbalenya, A. E.,
and Koonin, E. V.
(1993)
Sov. Sci. Rev. Sect. D Physicochem. Biol
11,
1-84
|
| 57.
|
Bonilla, P. J.,
Gorbalenya, A. E.,
and Weiss, S. R.
(1994)
Virology
198,
736-740
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. J. Gadlage, R. L. Graham, and M. R. Denison
Murine Coronaviruses Encoding nsp2 at Different Genomic Loci Have Altered Replication, Protein Expression, and Localization
J. Virol.,
December 1, 2008;
82(23):
11964 - 11969.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. W. Neuman, J. S. Joseph, K. S. Saikatendu, P. Serrano, A. Chatterjee, M. A. Johnson, L. Liao, J. P. Klaus, J. R. Yates III, K. Wuthrich, et al.
Proteomics Analysis Unravels the Functional Repertoire of Coronavirus Nonstructural Protein 3
J. Virol.,
June 1, 2008;
82(11):
5279 - 5294.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Tijms, D. D. Nedialkova, J. C. Zevenhoven-Dobbe, A. E. Gorbalenya, and E. J. Snijder
Arterivirus Subgenomic mRNA Synthesis and Virion Biogenesis Depend on the Multifunctional nsp1 Autoprotease
J. Virol.,
October 1, 2007;
81(19):
10496 - 10505.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Chen, Y. Wang, K. Ratia, A. D. Mesecar, K. D. Wilkinson, and S. C. Baker
Proteolytic Processing and Deubiquitinating Activity of Papain-Like Proteases of Human Coronavirus NL63
J. Virol.,
June 1, 2007;
81(11):
6007 - 6018.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Ziebuhr, B. Schelle, N. Karl, E. Minskaia, S. Bayer, S. G. Siddell, A. E. Gorbalenya, and V. Thiel
Human Coronavirus 229E Papain-Like Proteases Have Overlapping Specificities but Distinct Functions in Viral Replication
J. Virol.,
April 15, 2007;
81(8):
3922 - 3932.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. C. Y. Woo, M. Wang, S. K. P. Lau, H. Xu, R. W. S. Poon, R. Guo, B. H. L. Wong, K. Gao, H.-w. Tsoi, Y. Huang, et al.
Comparative Analysis of Twelve Genomes of Three Novel Group 2c and Group 2d Coronaviruses Reveals Unique Group and Subgroup Features
J. Virol.,
February 15, 2007;
81(4):
1574 - 1585.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. L. Graham and M. R. Denison
Replication of Murine Hepatitis Virus Is Regulated by Papain-Like Proteinase 1 Processing of Nonstructural Proteins 1, 2, and 3
J. Virol.,
December 1, 2006;
80(23):
11610 - 11620.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.-P. Egloff, H. Malet, A. Putics, M. Heinonen, H. Dutartre, A. Frangeul, A. Gruez, V. Campanacci, C. Cambillau, J. Ziebuhr, et al.
Structural and Functional Basis for ADP-Ribose and Poly(ADP-Ribose) Binding by Viral Macro Domains.
J. Virol.,
September 1, 2006;
80(17):
8493 - 8502.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ratia, K. S. Saikatendu, B. D. Santarsiero, N. Barretto, S. C. Baker, R. C. Stevens, and A. D. Mesecar
Severe acute respiratory syndrome coronavirus papain-like protease: Structure of a viral deubiquitinating enzyme
PNAS,
April 11, 2006;
103(15):
5717 - 5722.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Putics, A. E. Gorbalenya, and J. Ziebuhr
Identification of protease and ADP-ribose 1''-monophosphatase activities associated with transmissible gastroenteritis virus non-structural protein 3.
J. Gen. Virol.,
March 1, 2006;
87(Pt 3):
651 - 656.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Galan, L. Enjuanes, and F. Almazan
A Point Mutation within the Replicase Gene Differentially Affects Coronavirus Genome versus Minigenome Replication
J. Virol.,
December 15, 2005;
79(24):
15016 - 15026.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. A. Lindner, N. Fotouhi-Ardakani, V. Lytvyn, P. Lachance, T. Sulea, and R. Menard
The Papain-Like Protease from the Severe Acute Respiratory Syndrome Coronavirus Is a Deubiquitinating Enzyme
J. Virol.,
December 15, 2005;
79(24):
15199 - 15208.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Weiss and S. Navas-Martin
Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus
Microbiol. Mol. Biol. Rev.,
December 1, 2005;
69(4):
635 - 664.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. L. Graham, A. C. Sims, S. M. Brockway, R. S. Baric, and M. R. Denison
The nsp2 Replicase Proteins of Murine Hepatitis Virus and Severe Acute Respiratory Syndrome Coronavirus Are Dispensable for Viral Replication
J. Virol.,
November 1, 2005;
79(21):
13399 - 13411.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Putics, W. Filipowicz, J. Hall, A. E. Gorbalenya, and J. Ziebuhr
ADP-Ribose-1"-Monophosphatase: a Conserved Coronavirus Enzyme That Is Dispensable for Viral Replication in Tissue Culture
J. Virol.,
October 15, 2005;
79(20):
12721 - 12731.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-N. Chen, C. P. C. Lin, K.-K. Huang, W.-C. Chen, H.-P. Hsieh, P.-H. Liang, and J. T.-A. Hsu
Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3)
Evid. Based Complement. Altern. Med.,
June 1, 2005;
2(2):
209 - 215.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. R. Yang
Mining SARS-CoV protease cleavage data using non-orthogonal decision trees: a novel method for decisive template selection
Bioinformatics,
June 1, 2005;
21(11):
2644 - 2650.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Sulea, H. A. Lindner, E. O. Purisima, and R. Menard
Deubiquitination, a New Function of the Severe Acute Respiratory Syndrome Coronavirus Papain-Like Protease?
J. Virol.,
April 1, 2005;
79(7):
4550 - 4551.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Vijgen, E. Keyaerts, E. Moes, I. Thoelen, E. Wollants, P. Lemey, A.-M. Vandamme, and M. Van Ranst
Complete Genomic Sequence of Human Coronavirus OC43: Molecular Clock Analysis Suggests a Relatively Recent Zoonotic Coronavirus Transmission Event
J. Virol.,
February 1, 2005;
79(3):
1595 - 1604.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. H. Harcourt, D. Jukneliene, A. Kanjanahaluethai, J. Bechill, K. M. Severson, C. M. Smith, P. A. Rota, and S. C. Baker
Identification of Severe Acute Respiratory Syndrome Coronavirus Replicase Products and Characterization of Papain-Like Protease Activity
J. Virol.,
December 15, 2004;
78(24):
13600 - 13612.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Ivanov, T. Hertzig, M. Rozanov, S. Bayer, V. Thiel, A. E. Gorbalenya, and J. Ziebuhr
Major genetic marker of nidoviruses encodes a replicative endoribonuclease
PNAS,
August 24, 2004;
101(34):
12694 - 12699.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Ivanov and J. Ziebuhr
Human Coronavirus 229E Nonstructural Protein 13: Characterization of Duplex-Unwinding, Nucleoside Triphosphatase, and RNA 5'-Triphosphatase Activities
J. Virol.,
July 15, 2004;
78(14):
7833 - 7838.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Ivanov, V. Thiel, J. C. Dobbe, Y. van der Meer, E. J. Snijder, and J. Ziebuhr
Multiple Enzymatic Activities Associated with Severe Acute Respiratory Syndrome Coronavirus Helicase
J. Virol.,
June 1, 2004;
78(11):
5619 - 5632.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Denison, B. Yount, S. M. Brockway, R. L. Graham, A. C. Sims, X. Lu, and R. S. Baric
Cleavage between Replicase Proteins p28 and p65 of Mouse Hepatitis Virus Is Not Required for Virus Replication
J. Virol.,
June 1, 2004;
78(11):
5957 - 5965.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Thiel, K. A. Ivanov, A. Putics, T. Hertzig, B. Schelle, S. Bayer, B. Weissbrich, E. J. Snijder, H. Rabenau, H. W. Doerr, et al.
Mechanisms and enzymes involved in SARS coronavirus genome expression
J. Gen. Virol.,
September 1, 2003;
84(9):
2305 - 2315.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kanjanahaluethai, D. Jukneliene, and S. C. Baker
Identification of the Murine Coronavirus MP1 Cleavage Site Recognized by Papain-Like Proteinase 2
J. Virol.,
July 1, 2003;
77(13):
7376 - 7382.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. F. P. Ng and D. X. Liu
Membrane Association and Dimerization of a Cysteine-Rich, 16-Kilodalton Polypeptide Released from the C-Terminal Region of the Coronavirus Infectious Bronchitis Virus 1a Polyprotein
J. Virol.,
May 13, 2002;
76(12):
6257 - 6267.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Hegyi, A. Friebe, A. E. Gorbalenya, and J. Ziebuhr
Mutational analysis of the active centre of coronavirus 3C-like proteases
J. Gen. Virol.,
March 1, 2002;
83(3):
581 - 593.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Hegyi and J. Ziebuhr
Conservation of substrate specificities among coronavirus main proteases
J. Gen. Virol.,
March 1, 2002;
83(3):
595 - 599.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. N. Chouljenko, X. Q. Lin, J. Storz, K. G. Kousoulas, and A. E. Gorbalenya
Comparison of genomic and predicted amino acid sequences of respiratory and enteric bovine coronaviruses isolated from the same animal with fatal shipping pneumonia
J. Gen. Virol.,
December 1, 2001;
82(12):
2927 - 2933.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|